

Whitby J, Nitchingham A, Caplan G, Davis D, Tsui A. Persistent delirium in older hospital patients: an updated systematic review and meta-analysis. *Delirium*. Published online August 9, 2022.

#### Articles

# Persistent delirium in older hospital patients: an updated systematic review and meta-analysis

Jonathan Whitby<sup>1</sup>, Anita Nitchingham<sup>2</sup> , Gideon Caplan<sup>2</sup> , Daniel Davis<sup>1</sup> , Alex Tsui<sup>1</sup> <sup>a</sup> <sup>1</sup> MRC Unit for Lifelong Health and Ageing, University College London, <sup>2</sup> The Prince of Wales Clinical School, University of New South Wales Keywords: persistent delirium, systematic review, meta-regression, older people

## Delirium

#### Introduction

Delirium is associated with future dementia progression. Yet whether this occurs subclinically over months and years, or persistent delirium merges into worsened dementia is not understood. Our objective was to estimate the prevalence of persistent delirium and understand variation in its duration.

#### Methods

We adopted an identical search strategy to a previous systematic review, only including studies using a recognised diagnostic framework for ascertaining delirium at follow-up (persistent delirium). Studies included hospitalised older patients outside critical and palliative care settings. We searched MEDLINE, EMBASE, PsycINFO and the Cochrane Database of Systematic Reviews on 11th January 2022. We applied risk of bias assessments based on Standards of Reporting of Neurological Disorders criteria and assessed strength of recommendations using the grading of recommendation, assessment, development and evaluation (GRADE) approach. Estimates were pooled across studies using random-effects meta-analysis, and we estimated associations with follow-up duration using robust error meta-regression.

#### Results

We identified 13 new cohorts, which we added to 10 from the previous systematic review (23 relevant studies, with 39 reports of persistent delirium at 7 time-points in 3186 individuals admitted to hospital care (mean age 82 years and 41% dementia prevalence). Studies were mainly at moderate risk of bias. Pooled delirium prevalence estimates at discharge were 36% (95% CI 22% to 51%, 13 studies). Robust error meta-regression did not show variation in prevalence of persistent delirium over time (-1.6% per month, 95% CI -4.8 to 1.6, p=0.08). Margins estimates for this model indicate a prevalence of persistent delirium of 16% (95% CI 6% to 25%) at 12 months.

#### Conclusions

This systematic review emphasises the importance of delirium as a persistent and extensive problem (GRADE certainty = moderate), raising questions on chronic delirium as a clinical entity and how it might evolve into dementia. Addressing persistent delirium will require a whole-system, integrated approach to detect, follow-up and implement opportunities for recovery across all healthcare settings.

### INTRODUCTION

Delirium is particularly prevalent among older people and is associated with significant adverse outcomes, including long-term cognitive decline and increased mortality.<sup>1</sup> Several clinical guidelines and standards address its detection, prevention and management in hospitals.<sup>2–6</sup> Each of these recognises that questions remain over the natural history of

 a Correspondending author: Alex Tsui
 MRC Unit for Lifelong Health and Ageing at UCL
 1-19 Torrington Place
 London, WC1 7HB,
 UK
 a.tsui@ucl.ac.uk delirium, particularly in its relationship with dementia.<sup>7</sup> Although greater brain atrophy is associated with prolonged delirium, and incident delirium with future dementia progression,<sup>8–10</sup> whether underlying dementia leads to a more severe or prolonged delirium remains unknown.<sup>11,12</sup> In addition, the course and timeframe over which delirium-associated cognitive decline occurs, either stepwise or insidiously over months and years, or how persistent delirium symptoms phenotypically transform into worsened dementia, is not understood.

Persistent delirium is both a challenge to health care systems and a research opportunity.<sup>13</sup> First, there is no current clinical or academic consensus on how long delirium has to be present to be described as persistent. Defining start and end points of delirium is already challenging, particularly in the context of pre-existing dementia, when overlapping clinical features reduce specificity of both delirium and dementia screening instruments.<sup>8</sup> This potentially delays delirium recognition and prolongs it. Moreover, there is no agreement on the time between temporal clusters of delirium symptoms that would constitute a single episode. Overall, our understanding of how delirium resolves remains limited: do clinical features improve as a single entity or do deficits resolve at varying rates? Are resolution patterns heterogeneous among different patients with divergent cognitive prognoses?

Persistent delirium has been of academic interest since a systematic review from 2009 suggested one in five cases were still evident six months after discharge.<sup>14</sup> Subsequently, the number of older people presenting for urgent and emergency care has increased.<sup>15</sup> There has also been a consistent trend for more acute presentations of people living with dementia; around half are admitted within the first 12 months of diagnosis.<sup>16</sup> In light of these changes, we set out to update the systematic review to provide current estimates for the prevalence of persistent delirium and understand variation in its duration. For this review, persistent delirium was defined as an accepted diagnosis of delirium during admission and at follow-up, performed at least one week after initial assessment.

#### **METHODS**

#### ELIGIBILITY CRITERIA

We followed the 2020 PRISMA guidance.<sup>17</sup> We used the same criteria applied in the previous systematic review: (i) study population of at least 20 hospital patients; (ii) patients aged  $\geq$ 50 years; (iii) prospective study with follow-up of at least one week; (iv) acceptable definition of delirium at enrolment.<sup>14</sup> Only studies published in English or French were included. Studies investigating delirium in critical care and in the context of terminal illness or palliative care were excluded: we deemed delirium in these groups was likely to have been driven by setting specific precipitants, such as intubation, central venous access, anaesthesia and sedative medications, resulting in a population distinct from ward-based patients.

Our only modification required studies to use a recognised diagnostic framework for ascertaining delirium at follow-up (*persistent delirium*); studies from the original systematic review meeting this criterion were carried over into the current analysis. Given this was an update of a previous systematic review, we did not devise a *de novo* protocol for PROSPERO. Risk of bias assessments were based on Standards of Reporting of Neurological Disorders criteria and strength of recommendations were assessed using the grading of recommendation, assessment, development and evaluation (GRADE) approach.<sup>18,19</sup>

#### OUTCOME MEASURES

The *a priori* defined primary outcome was proportion of patients with delirium at follow-up, where the denominator was the number of participants who had delirium at inception, extracted as prevalence percentages. We considered any definition based on the Diagnostic and Statistical Manual (DSM), International Classification of Disease, the Confusion Assessment Method (CAM) or the Delirium Index to be sufficiently detailed to ascertain delirium reliably.<sup>20,21</sup>

#### SEARCH STRATEGY

Updating the original review, we searched from 1 year before the previous end date (September 2006) to 11<sup>th</sup> January 2022. We searched the same electronic databases: MED-LINE, EMBASE, PsycINFO and the Cochrane Database of Systematic Reviews, using the following search terms: Delirium [Title] AND (prognosis OR outcome OR aged OR occurrence) [Title/Abstract], replicating the original search strategy. We confirmed the sensitivity of the search by ensuring that we captured all studies identified by the previous review when we applied these terms to that review's timeframe.

#### DATA COLLECTION AND STUDY SELECTION

Covidence (www.covidence.org, Veritas Health Innovation Ltd.) was used to manage the abstract and full-text screening, assessing risk of bias and data extraction (including study characteristics, ascertainment methods, delirium prevalence at each time point, study-level mean age, study-level dementia prevalence). We also documented the duration of the delirium – usually the length of stay – where this was reported for persistent delirium at discharge. Three researchers independently reviewed titles and abstracts (J.W., A.N., A.T.) to determine the eligibility. Conflicts were resolved by discussion and consensus. The same reviewers extracted data using a *pro forma*.

#### ASSESSMENT OF QUALITY AND BIASES

Using the Standards of Reporting of Neurological Disorders criteria to determine risk of bias, we considered bias arising (i) from specific patient settings, e.g., general medical patients, cohorts with intracerebral haemorrhage; (ii) from sample selection, e.g., convenience, consecutive; (iii) from sample criteria, e.g., excluding patients unable to consent, assessed as being too sick; (iv) from reference standard used, e.g., DSM, CAM; (v) from expertise in applying the reference standard, e.g. routine data, dedicated researcher.<sup>19</sup> We rated studies *high*, *low* or *unclear* risk of bias in each of the five domains, graphically representing these

using the *robvis* app.<sup>22</sup> Strength of evidence was assessed using the GRADE framework, which takes into account risk of bias, inconsistency, indirectness, imprecision and publication bias.<sup>18</sup>

#### STATISTICAL ANALYSIS

We extracted prevalence of persistent delirium at each time point from within each study and calculated their standard errors (sqrt [p (1-p) / n)] and 95% confidence intervals. We assumed methodological heterogeneity across studies, accounting for this heterogeneity using DerSimonian–Laird random-effects models.<sup>23</sup> Statistical heterogeneity was assessed with the I<sup>2</sup> statistic. To assess publication bias, we plotted the estimated proportion of delirium occurrence against the standard error of that estimate and inspected the degree of asymmetry.

Our preliminary forest plots stratified the pooled data by length of follow-up. However, we found the estimates for *persistent delirium at discharge* reported a wide range of inpatient delirium durations (up to 30 days for one study<sup>24</sup>). Therefore, we corrected the reported follow-up duration to account for this initial difference. Where studies did not report initial delirium duration or length of stay (n=4), or they were conducted in a post-acute setting (n=3), we imputed the median delirium duration (6 days).

Meta-regression was used to estimate the relationship between persistent delirium and follow-up time, mean age (the commonest reported metric, mean age otherwise calculated from published summary statistics), and dementia prevalence in each study sample. Standard errors were estimated using permutations based on a Monte Carlo simulation procedure to account for clustered observations, where studies reported serial prevalence in the same cohort.<sup>25</sup> To further address the non-independence of these longitudinal observations, we used robust errors meta-regression to give summary estimates for persistent delirium over time.<sup>26</sup> We used Stata 17.0 (StataCorp, Texas) for all analyses.

#### RESULTS

We identified 6474 articles, screening 5556 after removing duplicates (Figure 1). We assessed 119 full-text articles for eligibility. We identified 13 new cohorts, which we added to 10 from the previous systematic review, giving a total of 23 relevant studies with 39 reports of persistent delirium at 7 time points in 3186 individuals (Table 1).<sup>24,27-48</sup> Most studies were in medical or surgical patients (14 medical; 9 surgical; 3 post-acute care; 2 stroke); all were from highincome settings. Case mix by ethnicity was not generally reported. Samples ranged in size (n=23 to n=590) and duration of follow-up (up to 18 months, 1 study). Mean age and proportion with dementia were 82 years and 41%, respectively, though both varied substantially between different study cohorts. Most studies either did not report details of dementia ascertainment or based it on a diagnosed medical history. However, two studies used the Blessed dementia scale<sup>33</sup> or a follow-up assessment at 3 months to determine whether DSM-IV-TR criteria for pre-index dementia could be retrospectively diagnosed.<sup>44</sup> One article from the original systematic review could not be directly accessed despite

extensive archival searches,<sup>28</sup> so we used secondary data reported in that review with appropriate caution in our risk of bias assessments for that study.

In the main, studies were at low risk of bias insofar as most followed a sample representative of the target setting (e.g., acute hospital care) and used consistent outcome ascertainment instruments. Around half excluded patients unable to give consent (and did not report procedures to allow proxy consent) and/or excluded participants too sick to assess for delirium (GRADE certainty rating for risk of bias = moderate) (Supplementary Figure 1). Case ascertainment was based on a consensus definition (e.g. DSM) in 9 studies; the rest used instruments such as CAM. Given each DSM definition has different degrees of restrictiveness,<sup>49</sup> the GRADE certainty rating for indirectness was moderate.

Pooled estimates for delirium prevalence at discharge was 36% (95% CI 22% to 51%, 13 studies) (Figure 2). Although there were few studies with data beyond 6 months, each time point reported considerable persistent cases (pooled estimates ranging from 3% to 59%). There was substantial statistical heterogeneity at all time points (all subgroup I<sup>2</sup> >89%). Funnel plots of prevalence versus the standard error of the estimate did not demonstrate any asymmetry, leading to a GRADE certainty rating for lack of publication bias as *high* (Supplementary Figure 2).

Robust error meta-regression did not show variation in prevalence of persistent delirium over time (-1.6% per month, 95% CI -4.8 to 1.6, p=0.08) (Table 2, Figure 3). The lack of monotonic decrease in prevalence over time led to a GRADE certainty rating for inconsistency as *moderate*. Older study sample age was not associated with higher prevalence of persistent delirium (1.5% per year, 95% CI -0.6% to 3.6%, Table 2). Persistent delirium did not vary with the proportion of study sample with dementia, though only 16 studies reported this (Table 2). Figure 3 shows the predicted robust error meta-regression for change in prevalence over time. Margins estimates for this model indicate a prevalence of persistent delirium of 16% (95% CI 6% to 25%) at 12 months (Figure 3). The GRADE certainty for rating for precision was *low*.

#### DISCUSSION

We showed that though individual estimates of prevalence differ substantially, persistent delirium can remain a problem well beyond the acute phase and indeed may never recover. This persistence does not appear to vary with a prior diagnosis of dementia, but the study-level ecological measure of dementia was unlikely to account for undiagnosed cognitive impairment. Neither was a clear association evident with mean age of the study sample. Taken together, these findings provide evidence for a chronic form of delirium that may merge with underlying dementia. Either way, there appears to be a considerable need to focus delirium recovery for both individuals and health services.

Our data should be considered in light of a number of limitations. Other than duration, the variables we could use for meta-regression relied on study-level data on mean sample age and dementia prevalence. Mean age might not have been the most appropriate summary measure in older cohorts. Interpreting meta-regression estimates may be

#### Table 1. Characteristics of included studies.

Study	Setting	Ν	Mean sample age (years)	Dementia (%)	Delirium ascertainment	Inpatient delirium duration (median)	Prevalence of persistent delirium						
							Discharge	2w	1m	3m	6m	12m	18m
Levkoff 1992 <sup>27</sup>	M, S	91	81		DSM-III	19 days	58%			37%	31%		
Gaudet 1993 <sup>28</sup>	М	52	85	39	DSM-IIIR	7 days	23%						
O'Keeffe 1997 <sup>24</sup>	М	94	82	46	DSM-III	30 days	1%						
Rudberg 1997 <sup>29</sup>	M, S	64	75	33	DSM-III-R	7 days	11%						
Marcantonio 2000 <sup>30</sup>	S	52	79	66	CAM	5 days	38%		29%		6%		
Kelly 2001 <sup>31</sup>	М	61	89		CAM	8 days	72%		46%	25%			
McCusker 2003 <sup>32</sup>	М	181	83	70	DSM-III-R	18 days	32%				32%	41%	
Kiely 2004 <sup>33</sup>	PAC	85	85	23	CAM	N/A			51%				
McAvay 2006 <sup>34</sup>	М	55	80	27	CAM	15 days	24%						
Inouye 2007 <sup>35</sup>	М	169	80	20	CAM	7 days	51%						
Lundstrom 2007 <sup>36</sup>	S	129	82	32	DSM-IV	10 days	12%						
Kiely 2009 <sup>37</sup>	PAC	412	84	38	CAM	N/A		67%	56%	40%	32%		
McManus 2009 <sup>38</sup>	Stroke	23	75		CAM				64%				
Arinzon 2011 <sup>39</sup>	М	92	80	90	CAM, DRS	16 days		50%					
Lee 2011 <sup>40</sup>	S	70	80	10	CAM				20%			13%	3%
Velilla 2012 <sup>41</sup>	М	45	87		DSM-IV				18%				
Witlox 2013 <sup>42</sup>	S	27	84		CAM					19%			
Cole 2015 <sup>43</sup>	M, S	278	85	55	CAM				73%	61%			
Jackson 2016 <sup>44</sup>	М	125	84	36	DSM-IV					6%			
Miu 2016 <sup>45</sup>	PAC	89	84		CAM	N/A	79%		85%	55%			
Vasunilashorn 2016 <sup>46</sup>	M, S	250	79		CAM		24%						
Cole 2017 <sup>47</sup>	M, S	152	85	52	CAM	14 days			63%				
Reznik 2022 <sup>48</sup>	Stroke	590	71	13	DSM-5		48%						

Dementia % refers to the proportion of participants in the individual study sample identified as living with dementia

% reported refer to the denominator of patients with delirium in the original sample.

M medical; S surgical; PAC post-acute care; DSM Diagnostic and Statistical Manual; CAM Confusion Assessment Method; DRS Delirium Rating Scale; DI Delirium Index



#### Figure 1. PRISMA flow diagram detailing study selection process.

\* One study included in original systematic review could not be directly retrieved, but it was possible to use data secondary reports. Reasons for exclusion at full

Table	2. ľ	Meta-res	ression	estimatin	g the	pro	portion	of in	dividual	s with	persistent	delirium
						P ~ ~	P	· · · · ·			peroreterre	

	β	R	andom effe estimates	ects	After robust standard errors			
			95% CI		р	95% CI		р
Time (per month)	23 studies 39 time points	-1.6	-3.4	0.7	0.06	-4.8	1.6	0.08
Age (per year)	23 studies 39 time points	1.5	-0.4	3.3	0.12	-0.6	3.6	0.13
Dementia %	16 studies 26 time points	0.2	-0.1	0.6	0.19	-0.4	0.8	0.23

 $\beta$  represents % change in prevalence of persistent delirium.

Confidence intervals estimated using random-effects meta-regression (left column) and after permuting with Monte Carlo simulations (right column)

Age refers to the mean age of the study sample

Dementia refers to % with dementia in the study sample

limited due to residual confounding for quantities such as frailty. Most studies had significant attrition due to mortality and loss to follow-up, though this might be expected to underestimate the true prevalence of persistent delirium. All included studies were performed in high-income countries, while all but one cohort involved acutely unwell patients, making it difficult to generalise our findings to other lower-income, community or elective settings. Our findings also do not apply to critical care or palliative care, specifically being unable to describe delirium in the terminal

#### Study

#### % Effect (95% Cl**j**Weight

Discharge	and the set of the		
Levkoff 1992	· · · - • -	0.58 (0.48, 0.68)	7.61
Gaudet 1993		0.23 (0.12, 0.34)	7.54
O'Keeffe 1997		0.01 (-0.01, 0.03)	7.89
Rudberg 1997		0.11 (0.03, 0.19)	7.73
Marcantonio 2000		0.38 (0.25, 0.51)	7.43
Kelly 2001		0.72 (0.61, 0.83)	7.55
McCusker 2003		0.32 (0.25, 0.38)	7.77
McAvay 2006		0.24 (0.13, 0.35)	7.55
Inouye 2007		0.51 (0.43, 0.59)	7.74
Lundstrom 2007	◆ !	0.12 (0.06, 0.18)	7.81
Vasunilashorn 2016	♦ !	0.24 (0.19, 0.29)	7.82
Miu 2016	• •	0.79 (0.71, 0.87)	7.70
Reznik 2022	1 •	0.48 (0.44, 0.52)	7.86
Subgroup (I-squared = 98.7%)	$\diamond$	0.36 (0.22, 0.51)	100.00
2 weeks			
Kiely 2009	1.	0.67 (0.62, 0.72)	53.77
Arinzon 2011	-+-	0.50 (0.40, 0.60)	46.23
Subgroup (I-squared = 88.7%)	$\diamond$	0.59 (0.43, 0.76)	100.00
<u>1 month</u>			
Marcantonio 2000	- <b>-</b>	0.29 (0.17, 0.41)	9.78
Kelly 2001	-+	0.46 (0.33, 0.59)	9.76
Kiely 2004		0.51 (0.40, 0.61)	10.00
Kiely 2009	•	0.56 (0.51, 0.61)	10.55
McManus 2009		0.64 (0.44, 0.84)	8.65
Lee 2011	· · · · · · · · · · · · · · · · · · ·	0.20 (0.11, 0.29)	10.15
Velilla 2013	_ <b>→</b> _ !	0.18 (0.07, 0.29)	9.93
Cole 2015	· •	0.73 (0.68, 0.78)	10.52
Miu 2016	· · · +	0.85 (0.78, 0.92)	10.35
Cole 2017	I 🔶	0.63 (0.55, 0.71)	10.32
Subgroup (I-squared = 96.0%)	$\diamond$	0.51 (0.37, 0.64)	100.00
<u>3 months</u>			
Levkoff 1992		0.37 (0.27, 0.47)	14.21
Kelly 2001		0.25 (0.14, 0.36)	14.09
Kiely 2009	•	0.40 (0.35, 0.45)	14.69
Witlox 2013		0.19 (0.04, 0.34)	13.50
Cole 2015	• •	0.61 (0.55, 0.67)	14.62
Miu 2016	· · · · ·	0.55 (0.45, 0.65)	14.16
Jackson 2016	♦ 1	0.06 (0.02, 0.10)	14.73
Subgroup (I-squared = 97.9%)	$\diamond$	0.35 (0.17, 0.53)	100.00
<u>6 months</u>			
Levkoff 1992		0.31 (0.21, 0.41)	23.52
Marcantonio 2000	● 1	0.06 (-0.00, 0.12)	25.26
McCusker 2003	1 <b>.</b>	0.31 (0.25, 0.38)	25.10
Kiely 2009	<b>!</b> ◆	0.32 (0.27, 0.37)	26.12
Subgroup (I-squared = 93.7%)	$\diamond$	0.25 (0.12, 0.38)	100.00
12 months			
McCusker 2003		0.41 (0.34, 0.48)	50.17
Lee 2011	- <b>-</b> I	0.13 (0.05, 0.21)	49.83
Subgroup (I-squared = 96.3%)		0.27 (-0.01, 0.55)	100.00
18 months			
Lee 2011	T	0.03 (-0.01, 0.07)	100.00
Subgroup (I-squared = .%)	P	0.03 (-0.01, 0.07)	100.00
I	-	1	1
-1	0	1	

Figure 2. Forest plot showing pooled estimates of persistent delirium, stratified by study follow-up period.

NOTE: Weights are from random-effects model



# Figure 3. Robust error meta-regression showing estimated prevalence of persistent delirium over time.

Solid line shows fitted meta-regression, with 95% CI (dashed lines). Circles are study estimates, proportional to sample size (inverse variance weighting).

phase. Many studies only included delirium detected in the first 24-48 hours of admission, which could have led to under-ascertainment. We addressed the degree of overlap between the reports of *delirium at discharge* and the earlier follow-up time points (2-weeks and 4-weeks) by using exact intervals where possible. Some publications only reported persistent delirium at discharge, and it is impossible to know how long these patients remained as cases. Similarly, it is unclear how long delirium might have been present before transfer for individuals admitted to post-acute care. For longer follow-up intervals, it would not have been possible to ascertain whether any incident delirium was persistent from the index event, or whether researchers were observing a second distinct episode of delirium. There was heterogeneity in delirium ascertainment measures. We also restricted our search to studies published in English or French, though only excluded one article based on publication language.

In updating the original systematic review with 15 years' worth of new studies, we have extended those findings to demonstrate persistent delirium remains a significant possibility for around one in eight older patients after 12 months. We could not identify risk factors for persistent delirium, nor was there consistent information to describe if clinical findings evolved into a dementia syndrome. More broadly, these data are consistent with terminal decline in cognition observed in longitudinal studies.<sup>50</sup> Higher education is associated with delayed onset of dementia, though

a faster trajectory once terminal decline begins.<sup>51</sup> Though previous cohorts have not considered delirium to be a driver, the Delirium and Population Health Informatics Cohort has shown that the largest post-delirium decline in cognition occurs in those with *higher* baseline cognition.<sup>52</sup> Dedicated prospective studies are needed to fully capture the influence of evolving dementia reciprocally affecting persistent delirium.

Persistent delirium offers a unique opportunity to better understand the pathophysiological mechanisms underlying delirium. We postulate the optimum window might occur when the patient remains delirious, but the initial medical or surgical insult has resolved, perhaps pragmatically defined as normalisation of laboratory abnormalities, healed surgical wounds and beyond the active lifespan of newly administered potentially delirium-culprit medications. Laboratory and neuroimaging investigations can be compared with features already present in patients with dementia, identifying any differing or additional pathophysiological mechanisms unique to delirium, not operating in patients with dementia alone.

The clinical implications of our findings indicate an urgent need to develop and evaluate delirium recovery and cognitive rehabilitation services. These services are almost non-existent, certainly out of proportion with the potential demand, though multicomponent interventions show promise.<sup>39</sup> Recognising the opportunities for the emerging field of interface acute geriatrics would be an important starting point,<sup>53</sup> and continued community-based management of delirium is likely to have an impact.<sup>54</sup> This systematic review emphasises the key importance of delirium as a persistent and extensive problem. Addressing persistent delirium will require a whole-system, integrated approach in order to detect, follow-up and implement opportunities for recovery across all healthcare settings.

#### ACKNOWLEDGEMENTS

JW is funded through a grant from the Dunhill Medical Association, DD is funded by the Wellcome Trust (WT107467). AT is an Alzheimer's Society Clinical Research Training Fellow. The MRC Unit for Lifelong Health and Ageing at UCL received core funding through the Medical Research Council (MC\_UU\_00019/1).

Submitted: March 08, 2022 CEST, Accepted: June 28, 2022 CEST



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-4.0). View this license's legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecommons.org/licenses/by/4.0/legalcode for more information.

# REFERENCES

1. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. *JAMA*. 2010;304(4):443-451. doi:10.1001/jama.2010.1013

2. Wilson JE, Mart MF, Cunningham C, et al. Delirium. *Nat Rev Dis Primers*. 2020;6(1):90. <u>doi:10.10</u> <u>38/s41572-020-00223-4</u>

3. Scottish Intercollegiate Guidelines Network (SIGN). *Risk Reduction and Management of Delirium*. SIGN 2019; 2019.

4. Australian Commission on Safety and Quality in Health Care. *Delirium Clinical Care Standard*. ACSQHC; 2021.

5. Gage L, Hogan DB. *2014 CCSMH Guideline Update: The Assessment and Treatment of Delirium*. Canadian Coalition for Seniors' Mental Health (CCSMH); 2014.

6. Bush SH, Marchington KL, Agar M, Davis DHJ, Sikora L, Tsang TWY. Quality of clinical practice guidelines in delirium: a systematic appraisal. *BMJ Open*. 2017;7(3):e013809. <u>doi:10.1136/bmjopen-201</u> <u>6-013809</u>

7. Davis, D.H.J., Kreisel, S.H., Muniz Terrera, G., Hall, A.J., Morandi, A., Boustani, M., Neufeld, K.J., Lee, H.C., MacLullich, A.M.J., Brayne, C. The epidemiology of delirium: challenges and opportunities for population studies. *Am J Geriatr Psychiatry*. 2013;21(12):1173-1189. doi:10.1016/j.jagp.2013.04.00 Z

8. Davis DH, Muniz Terrera G, Keage H, et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. *Brain*. 2012;135(Pt 9):2809-2816. doi:10.1093/brain/aws190

9. Gross AL, Jones RN, Habtemariam DA, et al. Delirium and long-term cognitive trajectory among persons with dementia. *Arch Intern Med*. 2012;172(17):1324-1331. <u>doi:10.1001/archinternme</u> <u>d.2012.3203</u>

10. Richardson SJ, Davis DHJ, Stephan BCM, et al. Recurrent delirium over 12 months predicts dementia: results of the Delirium and Cognitive Impact in Dementia (DECIDE) study. *Age Ageing*. 2021;50(3):914-920. doi:10.1093/ageing/afaa244

11. Morandi A, Bellelli G. Delirium superimposed on dementia. *Eur Geriatr Med*. 2020;11(1):53-62. <u>doi:10.1</u> <u>007/s41999-019-00261-6</u> 12. Gunther ML, Morandi A, Krauskopf E, et al. The association between brain volumes, delirium duration, and cognitive outcomes in intensive care unit survivors: the VISIONS cohort magnetic resonance imaging study\*. *Crit Care Med*. 2012;40(7):2022-2032. doi:10.1097/CCM.0b013e3182 50acc0

13. Caplan GA, Kvelde T, Lai C, Yap SL, Lin C, Hill MA. Cerebrospinal fluid in long-lasting delirium compared with Alzheimer's dementia. *J Gerontol A Biol Sci Med Sci.* 2010;65(10):1130-1136. <u>doi:10.1093/gerona/glq09</u> <u>0</u>

14. Cole MG, Ciampi A, Belzile E, Zhong L. Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. *Age Ageing*. 2009;38(1):19-26. doi:10.1093/ageing/afn253

15. Gruneir A, Silver MJ, Rochon PA. Emergency department use by older adults: a literature review on trends, appropriateness, and consequences of unmet health care needs. *Med Care Res Rev*. 2011;68(2):131-155. doi:10.1177/1077558710379422

16. Sommerlad A, Perera G, Mueller C, et al. Hospitalisation of people with dementia: evidence from English electronic health records from 2008 to 2016. *Eur J Epidemiol*. 2019;34(6):567-577. doi:10.100 7/s10654-019-00481-x

17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. do i:10.1136/bmj.n71

18. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-926. <u>doi:10.1136/bmj.39489.4703</u> <u>47.AD</u>

19. Bennett DA, Brayne C, Feigin VL, et al. Development of the Standards of Reporting of Neurological Disorders (STROND) checklist: A guideline for the reporting of inciden ce and prevalence studies in neuroe pidemiology. *Neurology*. 2015;85(9). <u>doi:10.1212/WNL.00000000001866</u>

20. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med*. 1990;113(12):941-948.

21. McCusker J, Cole MG, Dendukuri N, Belzile E. The delirium index, a measure of the severity of delirium: new findings on reliability, validity, and responsiveness. *J Am Geriatr Soc.* 2004;52(10):1744-1749. doi:10.1111/j.1532-5415.200 4.52471.x

22. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods*. 2021;12(1):55-61. doi:10.1002/jrsm.1411

23. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188.

24. O'Keeffe S, Lavan J. The prognostic significance of delirium in older hospital patients. *J Am Geriatr Soc*. 1997;45(2):174-178.

25. Harbord RM, Higgins JP. Meta-regression in Stata. *The Stata Journal*. 2008;8(4):493-519.

26. Xu C, Doi SAR. The robust error meta-regression method for dose-response meta-analysis. *Int J Evid Based Healthc*. 2018;16(3):138-144. <u>doi:10.1097/XE B.000000000000132</u>

27. Levkoff SE, Evans DA, Liptzin B, et al. Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. *Arch Intern Med*. 1992;152(2):334-340.

28. Gaudet, M., Pfitzenmeyer, P., Tavernier-Vidal, B., Lechenet, M. [Delirium in acute care geriatric hospital.]. *Psychologie Medicale*. 1993;25(7).

29. Rudberg MA, Pompei P, Foreman MD, Ross RE, Cassel CK. The natural history of delirium in older hospitalized patients: a syndrome of heterogeneity. *Age Ageing*. 1997;26(3):169-174.

30. Marcantonio ER, Flacker JM, Michaels M, Resnick NM. Delirium Is Independently Associated with Poor Functional Recovery After Hip Fracture. *J Am Geriatr Soc.* 2000;48(6):618-624.

31. Kelly KG, Zisselman M, Cutillo-Schmitter T, Reichard R, Payne D, Denman SJ. Severity and course of delirium in medically hospitalized nursing facility residents. *Am J Geriatr Psychiatry*. 2001;9(1):72-77.

32. McCusker J, Cole M, Dendukuri N, Han L, Belzile E. The course of delirium in older medical inpatients: a prospective study. *J Gen Intern Med*. 2003;18(9):696-704.

33. Kiely DK, Bergmann MA, Jones RN, Murphy KM, Orav EJ, Marcantonio ER. Characteristics associated with delirium persistence among newly admitted post-acute facility patients. *J Gerontol A Biol Sci Med Sci.* 2004;59(4):344-349. 34. McAvay GJ, Van Ness PH, Bogardus, S. T., Jr., et al. Older adults discharged from the hospital with delirium: 1-year outcomes. *J Am Geriatr Soc*. 2006;54(8):1245-1250. <u>doi:10.1111/j.1532-5415.200</u> 6.00815.x

35. Inouye SK, Zhang Y, Jones RN, Kiely DK, Yang F, Marcantonio ER. Risk factors for delirium at discharge: development and validation of a predictive model. *Arch Intern Med*. 2007;167(13):1406-1413. <u>do</u> <u>i:10.1001/archinte.167.13.1406</u>

36. Lundstrom M, Olofsson B, Stenvall M, et al. Postoperative delirium in old patients with femoral neck fracture: a randomized intervention study. *Aging Clin Exp Res.* 2007;19(3):178-186.

37. Kiely DK, Marcantonio ER, Inouye SK, et al. Persistent Delirium Predicts Greater Mortality. *J Am Geriatr Soc.* 2009;57(1):55-61. <u>doi:10.1111/j.1532-541</u> <u>5.2008.02092.x</u>

38. McManus J, Pathansali R, Hassan H, et al. The course of delirium in acute stroke. *Age Ageing*.
2009;38(4):385-389. doi:10.1093/ageing/afp038

39. Arinzon Z, Peisakh A, Schrire S, Berner YN.
Delirium in long-term care setting: indicator to severe morbidity. *Arch Gerontol Geriatr*.
2011;52(3):270-275. doi:10.1016/j.archger.2010.04.01
2

40. Lee KH, Ha YC, Lee YK, Kang H, Koo KH. Frequency, risk factors, and prognosis of prolonged delirium in elderly patients after hip fracture surgery. *Clin Orthop Relat Res.* 2011;469(9):2612-2620. <u>doi:1</u> 0.1007/s11999-011-1806-1

41. Velilla NM, Bouzon CA, Contin KC, Beroiz BI, Herrero AC, Renedo JA. Different functional outcomes in patients with delirium and subsyndromal delirium one month after hospital discharge. *Dement Geriatr Cogn Disord*. 2012;34(5-6):332-336. doi:10.115 9/000345609

42. Witlox J, Slor CJ, Jansen RW, et al. The neuropsychological sequelae of delirium in elderly patients with hip fracture three months after hospital discharge. *Int Psychogeriatr*. 2013;25(9):1521-1531. do i:10.1017/S1041610213000574

43. Cole MG, Bailey R, Bonnycastle M, et al. Partial and No Recovery from Delirium in Older Hospitalized Adults: Frequency and Baseline Risk Factors. *J Am Geriatr Soc.* 2015;63(11):2340-2348. <u>doi:10.1111/jgs.1</u> 3791 44. Jackson TA, MacLullich AMJ, Gladman JRF, Lord JM, Sheehan B. Undiagnosed long-term cognitive impairment in acutely hospitalised older medical patients with delirium: a prospective cohort study. *Age Ageing.* 2016;45(4):493-499. <u>doi:10.1093/ageing/a fw064</u>

45. Miu DK, Chan CW, Kok C. Delirium among elderly patients admitted to a post-acute care facility and 3-months outcome. *Geriatr Gerontol Int.* 2016;16(5):586-592. doi:10.1111/ggi.12521

46. Vasunilashorn SM, Marcantonio ER, Gou Y, et al. Quantifying the Severity of a Delirium Episode Throughout Hospitalization: the Combined Importance of Intensity and Duration. *J Gen Intern Med.* 2016;31(10):1164-1171. doi:10.1007/s11606-01 <u>6-3671-9</u>

47. Cole MG, McCusker J, Bailey R, et al. Partial and no recovery from delirium after hospital discharge predict increased adverse events. *Age Ageing*. 2017;46(1):90-95. doi:10.1093/ageing/afw153

48. Reznik ME, Margolis SA, Mahta A, et al. Impact of Delirium on Outcomes After Intracerebral Hemorrhage. *Stroke*. 2022;53(2):505-513. <u>doi:10.116</u> <u>1/STROKEAHA.120.034023</u>

49. Gibb K, Seeley A, Quinn T, et al. The consistent burden in published estimates of delirium occurrence in medical inpatients over four decades: a systematic review and meta-analysis study. *Age Ageing*. 2020;49(3):352-360. doi:10.1093/ageing/afaa040 50. Muniz-Terrera G, Matthews FE, Stephan B, Brayne C. Are terminal decline and its potential indicators detectable in population studies of the oldest old? *Int J Geriatr Psychiatry*. 2011;26(6):584-592. <u>doi:10.1002/gps.2566</u>

51. Terrera GM, Minett T, Brayne C, Matthews FE. Education associated with a delayed onset of terminal decline. *Age Ageing*. 2014;43(1):26-31. <u>doi:10.1093/ag</u> <u>eing/aft150</u>

52. Tsui A, Searle SD, Bowden H, et al. The effect of baseline cognition and delirium on long-term cognitive impairment and mortality: a prospective population-based study. *Lancet Healthy Longev*. 2022;3(4):e232-e241. doi:10.1016/S2666-7568(22)000 13-7

53. Rahman S, Byatt K. Follow-up services for delirium after COVID-19-where now? *Age Ageing*. 2021;50(3):601-604. <u>doi:10.1093/ageing/afab014</u>

54. Caplan GA, Coconis J, Board N, Sayers A, Woods J. Does home treatment affect delirium? A randomised controlled trial of rehabilitation of elderly and care at home or usual treatment (The REACH-OUT trial). *Age Ageing*. 2006;35(1):53-60. doi:10.1093/ageing/afi206

# SUPPLEMENTARY MATERIALS

# Prisma 2020 Checklist

Download: https://deliriumjournal.com/article/36822-persistent-delirium-in-older-hospital-patients-an-updated-systematic-review-and-meta-analysis/attachment/93923.docx

# **Supplementary Figure Files**

Download: https://deliriumjournal.com/article/36822-persistent-delirium-in-older-hospital-patients-an-updated-systematic-review-and-meta-analysis/attachment/93924.docx